(19) World Intellectual Property Organization International Burcau



(43) International Publication Date 31 March 2005 (31.03.2005)

(10) International Publication Number WO 2005/029090 A1

- (51) International Patent Classification7: G01N 33/68, 33/53, C12N 9/66, C12Q 1/68, A61K 38/57, C07K 14/81
- (21) International Application Number:

PC17SE2004/001378

(22) International Filing Date:

24 September 2004 (24.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0302559-0

25 September 2003 (25.09.2003)

- (71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BROBERG, Per [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). FEHNIGER, Thomas [US/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). MARKO-VARGA, György [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). UEBEL, Stephan [DE/DE]; Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried (DE).

- (74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DY, EC, BE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, IT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH. PL. PT. RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Liurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PI., PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCI Gazette.

(54) Title: ELASTIN PEPTIDE FINGERPRINTS AND ANALYSIS METHODS FOR MMP12 RELATED TO COPD

(57) Abstract: Methods for producing and using protein/peptide fingerprints, allowing identification and investigation of discaseassociated proteins/peptides that can be linked to specific drug targets, or to specific drug target combinations. The methods are particularly useful for studies relating to Chronic Obstructive Pulmonary Disease (COPD), especially for the enzyme MMP12.